Genitourinary Radiology

PET/CT-based model predicts prostate cancer in the 'PSA grey zone'
Combining PET/CT with traditional clinical risk factors can detect prostate cancer in cases considered borderline based on prostate-specific antigen (PSA) levels -- in other words, cases in the "PSA grey zone," according to a group in Hunan, China.
September 10, 2023
2023 09 08 15 10 4007 2023 09 08 Prostate Cancer 20230908154926
COVID-19 pandemic led to apparent decreases in cancer incidence
The COVID-19 pandemic led to apparent decreases in cancer incidence for several cancer types, suggest Canadian findings published September 5 in JAMA Network Open.
September 5, 2023
2023 09 05 21 24 9441 Covid 19 Second Wave 400
PET/CT and PET/MRI appear equivalent for diagnosing prostate cancer
PET/CT and PET/MRI have gone head-to-head for detecting prostate cancer relapse in a review that included 37 clinical studies and 8,709 patients -- with PET/MRI taking a slight lead, according to a team in China.
August 31, 2023
2019 04 17 20 48 2514 Prostate 3 D 400
CLS Americas inks partnership with Focalyx
Clinical Laserthermia Systems (CLS) Americas has inked a comarketing agreement with Focalyx for image-guided focal laser ablation of prostate tumors.
August 27, 2023
2019 04 17 20 48 2514 Prostate 3 D 400
Are PSMA-PET tracers equal in detecting prostate cancer?
Researchers in China have provided some clarity for clinicians over which prostate-specific membrane antigen (PSMA) radiotracer may be best for PET/CT prostate cancer imaging, according to a study published August 21 in Cancer Imaging.
August 27, 2023
2019 04 17 20 48 2514 Prostate 3 D 400
Telix posts 2023 half-year report
Telix Pharmaceuticals reported a spike in revenue for the first half of 2023, citing strong sales of its Illucix kit for preparing gallium-68 gozetotide injections for PET prostate cancer imaging.
August 22, 2023
2016 12 23 14 10 03 523 Graph Bar Arrow Up 400
AI developed for SPECT kidney imaging in children
An AI model based on SPECT images has the potential to help nuclear medicine physicians identify kidney defects in children, according to a research group in Taiwan.
August 16, 2023
2016 08 23 17 04 30 620 Kidney 400
Clarity advances dose escalation for cohort in SECuRE trial
Radiopharmaceutical developer Clarity Pharmaceuticals is highlighting the completion of the second cohort, as well as the advancement to the third cohort in the dose escalation phase of its phase I/II theranostic trial, SECuRE.
August 9, 2023
2021 01 16 00 14 5464 Prostate Cancer 400
MRI fusion-targeted plus systematic biopsy identifies prostate cancer
The combination of ultrasound and MRI fusion-targeted biopsies with systematic biopsies is more effective for identifying suspicious lesions than systematic biopsies alone, a study published July 25 in Radiology has found.
July 25, 2023
2023 07 25 21 31 5449 2023 07 25 Radiology Wei Figure4 20230725212024
NCCN adds Blue Earth's Posluma to its oncology guidelines
The National Comprehensive Cancer Network (NCCN) has added Blue Earth Diagnostics' Posluma (Flotufolastat F-18) PET radiotracer to its oncology guidelines for imaging prostate cancer.
July 24, 2023
2019 04 17 20 48 2514 Prostate 3 D 400
Pluvicto patient response criteria validated
Doctors now have a reliable approach for determining whether prostate cancer patients are responding to prostate cancer treatment with Pluvicto, according to research published July 11 in Radiology.
July 11, 2023
2023 07 12 00 54 5326 2023 07 12 Recip 20230712000635
Presurgical MRI predicts cancer recurrence after prostatectomy
Preprostatectomy, MRI-based staging features perform comparably to postsurgical pathologic staging features for predicting whether prostate cancer will recur, according to a study published July 5 in the American Journal of Roentgenology.
July 5, 2023
2021 01 16 00 14 5464 Prostate Cancer 400
Page 1 of 89
Next Page